Literature DB >> 26399288

Double trouble: tuberculosis and substance abuse in Nagaland, India.

R Shenoy1, M Das1, H Mansoor1, R Anicete1, L Wangshu1, S Meren2, I Ao3, P Saranchuk4, A J Reid5, P Isaakidis6.   

Abstract

The diagnosis and treatment of tuberculosis (TB) in people who use and/or inject illicit drugs (PWUIDs) remains a barrier to achieving universal coverage for TB in India and globally. This report describes treatment outcomes in PWUIDs who received treatment for drug-susceptible TB at the Mon District Hospital in Nagaland, India, during 2012-2013. The median age of the patients was 39 years, and most (92%) were male. Two thirds (33/49) of the patients had a successful TB treatment outcome. A previous TB episode and residence in a semi-urban area were associated with unsuccessful treatment outcomes. Separate diagnostic and treatment algorithms, including regular adherence counselling and opioid substitution therapies, should be considered for PWUIDs.

Entities:  

Keywords:  IDU; adherence; operational research; opium

Year:  2015        PMID: 26399288      PMCID: PMC4576769          DOI: 10.5588/pha.15.0019

Source DB:  PubMed          Journal:  Public Health Action        ISSN: 2220-8372


  3 in total

1.  A randomized trial comparing standard outcomes in two treatment models for substance users with tuberculosis.

Authors:  P M Ricks; R C Hershow; A Rahimian; D Huo; W Johnson; N Prachand; A Jimenez; W Wiebel; W Paul
Journal:  Int J Tuberc Lung Dis       Date:  2015-03       Impact factor: 2.373

2.  Managing tuberculosis in people who use and inject illicit drugs.

Authors:  Haileyesus Getahun; Annabel Baddeley; Mario Raviglione
Journal:  Bull World Health Organ       Date:  2013-02-01       Impact factor: 9.408

3.  Self-administered tuberculosis treatment outcomes in a tribal population on the indo-myanmar border, Nagaland, India.

Authors:  Mrinalini Das; Petros Isaakidis; Rahul Shenoy; Rey Anicete; Hemant Kumar Sharma; Imyangluba Ao; Kaikho Osah; Homa Mansoor; Peter Saranchuk; Sunita Abraham
Journal:  PLoS One       Date:  2014-09-26       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.